This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Biotech: 3 Profitable Bios Worth Owning
by Andrew Rocco
The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.
GILDPositive Net Change MRNANegative Net Change CPRXPositive Net Change
biotechnology biotechs
Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy
by Zacks Equity Research
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.
GILDPositive Net Change IMGNPositive Net Change JNCEPositive Net Change ACLXNegative Net Change
biotechnology biotechs
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
by Zacks Equity Research
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
GSKPositive Net Change PCRXNegative Net Change GLPGNegative Net Change VIRNegative Net Change
biotechnology biotechs pharmaceuticals
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
by Zacks Equity Research
Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.
GSKPositive Net Change GILDPositive Net Change SNDXPositive Net Change IMCRNegative Net Change
biotechnology medical
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.
MLABPositive Net Change EGOPositive Net Change ADAPNegative Net Change KMDANegative Net Change ZYMENegative Net Change
biotechnology gold medical
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
by Zacks Equity Research
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.
GILDPositive Net Change GSKPositive Net Change SNDXPositive Net Change IMCRNegative Net Change
biotechnology biotechs
Builders FirstSource (BLDR) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BLDRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
ADAPNegative Net Change KMDANegative Net Change ZYMENegative Net Change
biotechnology biotechs cancer cell-therapy coronavirus immuno-therapy inflation medical
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
by Zacks Equity Research
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
GSKPositive Net Change JNJPositive Net Change GILDPositive Net Change
biotechnology pharmaceuticals
Biotech is Set for a Blockbuster 2023: Here's Why
by Andrew Rocco
The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?
MRKPositive Net Change GILDPositive Net Change MRNANegative Net Change IBBNegative Net Change QQQNegative Net Change SPYNegative Net Change XBINegative Net Change
biotechnology biotechs
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More
by Ekta Bagri
Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.
GILDPositive Net Change MDGLPositive Net Change RCUSNegative Net Change TRDANegative Net Change
biotechnology biotechs
After Golden Cross, Assertio (ASRT)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ASRTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Greenwich LifeSciences, Inc. (GLSI)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
GLSIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Warner Music Group Corp. (WMG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
WMGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
LLYPositive Net Change UTHRNegative Net Change IMCRNegative Net Change
biotechnology pharmaceuticals
Entrada (TRDA) Down on Regulatory Update for DMD Candidate
by Zacks Equity Research
Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.
GILDPositive Net Change VRTXNegative Net Change KPositive Net Change KALAPositive Net Change TRDANegative Net Change
biotechnology pharmaceuticals
bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA
by Zacks Equity Research
bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.
GILDPositive Net Change KALAPositive Net Change IMCRNegative Net Change
biotechnology pharmaceuticals
Stock Market News for Dec 19, 2022
by Zacks Equity Research
U.S. stock markets closed sharply lower On Friday as market participants remained concerned about a recession in 2023.
MRNANegative Net Change
biotechnology
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
BCRXNegative Net Change GILDPositive Net Change VTGNPositive Net Change VIRNegative Net Change
biotechnology pharmaceuticals
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
AMGNPositive Net Change GILDPositive Net Change CYTKNegative Net Change VTGNPositive Net Change
biotechnology biotechs pharmaceuticals
5 Momentum Stock Bargains Hunters Would Love Chasing
by Debdutta Sinha
Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.
SNYNegative Net Change GSKPositive Net Change UALNegative Net Change UTHRNegative Net Change ULTANegative Net Change
biotechnology pharmaceuticals
Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left
by Nalak Das
we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.
UTHRNegative Net Change LPLANegative Net Change ENPHPositive Net Change SWAVPositive Net Change
alt-energy biotechnology finance medical oil-energy
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
AMGNPositive Net Change GILDPositive Net Change VRTXNegative Net Change HZNPPositive Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, Yext (YEXT)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
YEXTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Hecla Mining (HL)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
HLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines